Breaking News Instant updates and real-time market news.

SLS

Sellas Life Sciences

$1.00

-0.015 (-1.48%)

, BMY

Bristol-Myers

$46.45

0.16 (0.35%)

08:36
04/04/19
04/04
08:36
04/04/19
08:36

Sellas Life Sciences, MSK to study GPS with nivolumab in patients with MPM

Sellas Life Sciences (SLS) announced agreement with Memorial Sloan Kettering Cancer Center, or MSK, for the conduct of an investigator-sponsored clinical trial of Sellas' Wilms tumor-1, or WT1-targeting peptide immunotherapeutic agent, galinpepimut-S, or GPS, in combination with Bristol-Myers Squibb's (BMY) anti-PD-1 therapy, nivolumab, in patients with malignant pleural mesothelioma, or MPM. The Phase 1 open-label clinical study will enroll patients with MPM who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy with study drug provided by both Sellas and Bristol-Myers Squibb. The purpose of the trial is to determine if the administration of GPS in combination with nivolumab has the potential to demonstrate antitumor immune responses and meaningful clinical activity in the presence of macroscopic disease in MPM patients. The study will also investigate the tolerability of the combination, evaluate the immunogenicity of the two agents administered together, by CD4+ and CD8+ T-lymphocytes and gauge the degree of clinical benefit by assessment of the overall response rate with the combination in comparison with that reported with nivolumab alone in historical comparable patient populations. In a randomized, controlled, blinded Phase 2 clinical trial in MPM patients completed in 2017, GPS monotherapy, given as maintenance after first line tumor-debulking multimodality treatment, demonstrated meaningful clinical activity with median survival of 22.8 months vs. 18.3 months in the control group and with associated sustained immune responses against the WT1 antigen while adverse events were mainly comprised of low grade reactions at the site of the injection.

SLS

Sellas Life Sciences

$1.00

-0.015 (-1.48%)

BMY

Bristol-Myers

$46.45

0.16 (0.35%)

  • 08

    Apr

  • 10

    Apr

  • 12

    Apr

  • 17

    Apr

  • 25

    Apr

  • 18

    May

  • 20

    May

SLS Sellas Life Sciences
$1.00

-0.015 (-1.48%)

11/01/18
OPCO
11/01/18
INITIATION
Target $13
OPCO
Outperform
Sellas Life Sciences initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Sellas Life Sciences with an Outperform rating and $13 price target. With two late-stage clinical programs nearing pivotal trials and a robust early stage pipeline, the analyst believes Sellas Life Sciences is "highly undervalued" at sub-$50M in market cap. Cancer vaccines have had a convoluted history, but Singh believes this is an area for potential investor outperformance.
11/01/18
11/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Roth Capital. 2. T-Mobile (TMUS) initiated with a Buy at Guggenheim. 3. Kosmos (KOS) initiated with a Buy at Berenberg. 4. Sellas Life Sciences (SLS) initiated with an Outperform at Oppenheimer. 5. OFS Credit (OCCI) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/22/19
MAXM
03/22/19
DOWNGRADE
MAXM
Hold
Sellas Life Sciences downgraded to Hold from Buy at Maxim
03/25/19
03/25/19
DOWNGRADE

Hold
Sellas Life Sciences downgraded to Hold from Buy at Maxim
As previously reported, Maxim analyst Jason McCarthy downgraded Sellas Life Sciences to Hold, saying the company's "tight" cash balance will likely require it to raise capital to support the planned Phase 3 study of galinpepimut-S, or GPS. The analyst maintains however that Sellas Life Sciences fundamentals remain intact, and his positive views around GPS and Nelipepimut-S, or NPS, remain unchanged.
BMY Bristol-Myers
$46.45

0.16 (0.35%)

03/20/19
BMOC
03/20/19
NO CHANGE
Target $62
BMOC
Outperform
Bristol-Myers price target raised to $62 from $59 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Bristol-Myers (BMY) to $62 and kept his Outperform rating, saying its proposed Celgene (CELG) merger is the "right step at the right time." The analyst contends that the company needs to diversify its offerings because of the volatility in immuno-oncology and also boost its long term growth prospects because of the loss of exclusivity for its Eliquis and Opdivo products. Arfaei believes that the combined company will be "meaningfully more diversified and in a better position to fill patent cliffs during 2025-2030" period.
04/01/19
WBLR
04/01/19
DOWNGRADE
WBLR
Market Perform
Celgene downgraded to Market Perform from Outperform at William Blair
William Blair analyst Andy Hsieh downgraded Celgene (CELG) to Market Perform from Outperform saying the recent proxy recommendations set the course for the takeover by Bristol-Myers Squibb (BMY) winning shareholder approval.
04/01/19
UBSW
04/01/19
DOWNGRADE
Target $102
UBSW
Neutral
Celgene downgraded to Neutral from Buy at UBS
UBS analyst Carter Gould downgraded Celgene (CELG) to Neutral from Buy while raising his price target for the shares to $102 from $94. After ISS and Glass Lewis on Friday recommended that Bristol-Myers Squibb (BMY) shareholders vote in favor of the proposed acquisition, and Starboard dropped its proxy solicitation in opposition, the analyst sees an increasingly high probability that Bristol's acquisition of Celgene will be completed. He sees any lingering risks around antitrust concerns and Revlimid litigation as unlikely to derail the deal.
04/02/19
BERN
04/02/19
DOWNGRADE
BERN
Market Perform
Celgene downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Aaron Gal downgraded Celgene (CELG) to Market Perform from Outperform as spread narrows. The analyst notes that the current controversy on Celgene is whether the Bristol-Myers (BMY) acquisition will close. With limited upside, no differentiated views on the main controversy, and ahead of the shareholder vote on April 12th, the analyst is moving to the sidelines.

TODAY'S FREE FLY STORIES

SCOR

comScore

$12.91

-0.38 (-2.86%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
comScore names Kathy Bachmann as COO, effective April 17 »

On April 12, the Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

SRE

Sempra Energy

$127.42

0.1 (0.08%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
Sempra Energy receives FERC authorization for Texas project »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 21

    May

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

, BA

Boeing

$380.02

2.48 (0.66%)

16:45
04/18/19
04/18
16:45
04/18/19
16:45
Hot Stocks
Boeing, Spirit Aero reach pact to cover production costs for B737 program »

According to a regulatory…

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

BA

Boeing

$380.02

2.48 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 29

    May

  • 05

    Jun

16:45
04/18/19
04/18
16:45
04/18/19
16:45
General news
Treasury Market Summary: »

Treasury Market Summary:…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Fed Balance Sheet Level data reported »

Week of 4/17 Fed Balance…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Money Supply M2 Weekly Change data reported »

Week of 4/8 Money Supply…

BLK

BlackRock

$465.67

-1.99 (-0.43%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
Hot Stocks
BlackRock CFO sells 2,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 27

    Oct

TRV

Travelers

$138.82

2.93 (2.16%)

, HON

Honeywell

$169.01

6.09 (3.74%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

The S&P 500 notched a…

TRV

Travelers

$138.82

2.93 (2.16%)

HON

Honeywell

$169.01

6.09 (3.74%)

AXP

American Express

$113.67

1.89 (1.69%)

PM

Philip Morris

$84.53

-0.96 (-1.12%)

ZM

Zoom Video

$62.00

(0.00%)

PINS

Pinterest

$24.46

(0.00%)

CGC

Canopy Growth

$44.43

1.6 (3.74%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

FB

Facebook

$178.28

-0.49 (-0.27%)

BX

Blackstone

$38.65

2.74 (7.63%)

ADTN

Adtran

$16.60

2.055 (14.13%)

URI

United Rentals

$136.05

10.25 (8.15%)

CHKP

Check Point

$120.01

-9.56 (-7.38%)

SNBR

Sleep Number

$39.23

-8.76 (-18.25%)

SKX

Skechers

$31.60

-3.68 (-10.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 14

    May

  • 14

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 13

    Nov

  • 18

    Apr

  • 18

    Apr

GBCI

Glacier Bancorp

$41.70

-0.7 (-1.65%)

16:36
04/18/19
04/18
16:36
04/18/19
16:36
Earnings
Glacier Bancorp reports Q1 EPS 58c, consensus 58c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 24

    Apr

BLMN

Bloomin' Brands

$19.24

0.42 (2.23%)

16:34
04/18/19
04/18
16:34
04/18/19
16:34
Recommendations
Bloomin' Brands analyst commentary at Tigress Financial »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 30

    Apr

APHA

Aphria

$7.65

-0.165 (-2.11%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
Aphria subsidiary secures cannabis cultivation license in Germany »

Aphria Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

, SO

Southern Company

$51.95

-0.22 (-0.42%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
CenterPoint Energy names Xia Liu as CFO, effective April 22 »

CenterPoint Energy (CNP)…

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

SO

Southern Company

$51.95

-0.22 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

  • 09

    May

  • 21

    May

  • 21

    May

BANF

BancFirst

$55.58

-0.34 (-0.61%)

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Earnings
BancFirst reports Q1 EPS 96c, consensus 92c »

At March 31, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

16:28
04/18/19
04/18
16:28
04/18/19
16:28
Hot Stocks
Zosano Pharma CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$31.46

-0.16 (-0.51%)

16:26
04/18/19
04/18
16:26
04/18/19
16:26
Hot Stocks
Elizabethtown Gas files rate case with NJBPU »

Elizabethtown Gas, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

BCBP

BCB Bancorp

$13.09

0.08 (0.61%)

16:21
04/18/19
04/18
16:21
04/18/19
16:21
Earnings
BCB Bancorp reports Q1 EPS 32c, consensus 30c »

Total cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
04/18/19
04/18
16:20
04/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for April 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKE

Oneok

$69.13

-0.59 (-0.85%)

16:17
04/18/19
04/18
16:17
04/18/19
16:17
Hot Stocks
Oneok increases quarterly dividend 9% to 86.5c per share »

Oneok increased its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 22

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
04/18/19
04/18
16:17
04/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
04/18/19
04/18
16:16
04/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEP

Holly Energy Partners

$28.23

0.51 (1.84%)

16:16
04/18/19
04/18
16:16
04/18/19
16:16
Hot Stocks
Holly Energy Partners raises dividend to 67c per unit from 66.75c »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

HES

Hess Corp.

$65.87

-0.05 (-0.08%)

16:15
04/18/19
04/18
16:15
04/18/19
16:15
Hot Stocks
Hess Corp. announces 13th discovery offshore Guyana »

Hess Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 22

    May

  • 29

    May

16:15
04/18/19
04/18
16:15
04/18/19
16:15
General news
Breaking General news story  »

Week of 4/17 Fed Balance…

16:15
04/18/19
04/18
16:15
04/18/19
16:15
General news
Breaking General news story  »

Week of 4/8 Money Supply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.